Together these data confirm the variable response of breast cancer cells to EGFR targeted therapies suggest that reduced AnxA6 expression may be more relevant in breast cancer subtypes such as EGFR expressing invasive basal-like breast cancer. The gene discussed is ANXA6; the disease is breast cancer.